A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model

Archives of Toxicology

Volumn 88, Issue 7, 2014, Pages 1439-1449

  Chen, Minjun ^a   Tung, Chun Wei ^a,b   Shi, Qiang ^a   Guo, Lei ^a   Shi, Leming ^c   Fang, Hong ^a   Borlak, Jürgen ^d   Tong, Weida ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c FUDAN UNIVERSITY   (China)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

DILI; Drug safety assessment; Drug induced liver injury; High content screening assay; Primary rat hepatocytes

Indexed keywords

AMIODARONE; AZATHIOPRINE; BIOTIN; BUSPIRONE; BUSULFAN; CHLORPROMAZINE; CISPLATIN; CLONIDINE; CYCLOFENIL; CYCLOSPORIN; ETRETIN; FLUTAMIDE; HYDROCORTISONE; ISOPRENALINE; LORATADINE; MEBENDAZOLE; METHOTREXATE; MOXISYLYTE; NALTREXONE; NEFAZODONE; NIFEDIPINE; NOMIFENSINE; OXYPHENONIUM BROMIDE; PHYSOSTIGMINE; PINACIDIL; PROGESTERONE; TAMOXIFEN; UNINDEXED DRUG; VERAPAMIL; ZAFIRLUKAST; DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL LOSS; CYTOKINE RELEASE; DNA FRAGMENTATION; HIGH CONTENT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; LIVER CELL; LIVER INJURY; LIVER TOXICITY; LYSOSOMAL MASS; LYSOSOME; MALE; MASS; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; NUCLEAR SIZE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RAT; SCREENING; STEATOSIS; TASK PERFORMANCE; TOXIC HEPATITIS; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIGH THROUGHPUT SCREENING; ORAL DRUG ADMINISTRATION; PROCEDURES; RISK; SPRAGUE DAWLEY RAT; VALIDATION STUDY;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; RISK;

EID: 84903442033     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1276-9     Document Type: Article

References (37)

1. Andersen ME, Krewski D (2009) Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci 107:324-330
2. Bleicher KH, Bohm HJ, Muller K, Alanine AI (2003) Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2:369-378 (Pubitemid 37361707)
3. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W (2011) FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 16:697-703
4. Chen M, Zhang M, Borlak J, Tong W (2012) A decade of toxicogenomic research and its contribution to toxicological science. Toxicol Sci 130:217-228
5. Chen M, Borlak J, Tong W (2013a) High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58:388-396
6. Chen M, Hong H, Fang H, Zhou G, Kelly R, Borlak J, Tong W (2013b) Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. Toxicol Sci 136:242-249
7. Chen M, Zhang J, Wang Y, Liu Z, Kelly R, Zhou G, Fang H, Borlak J, Tong W (2013c) Liver toxicity knowledge base (LTKB) - a systems approach to a complex endpoint. Clin Pharmacol Ther 95:409-412
8. Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W (2014) Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomark Med 8:201-213
9. Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, Griffith LG, Sorger PK, Tidor B, Xu JJ, Lauffenburger DA (2009) Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflamma-tion- associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 237:317-330
10. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, Smith AR, Will Y (2008) In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103:335-345 (Pubitemid 351659605)
11. Ekins S, Williams AJ, Xu JJ (2010) A predictive ligand-based bayesian model for human drug induced liver injury. Drug Metab Dispos 38:2302-2308
12. Gomez-Lechon MJ, Lahoz A, Gombau L, Castell JV, Donato MT (2010) In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des 16:1963-1977
13. Greene N, Fisk L, Naven RT, Note R, Patel ML, Pelletier DJ (2010) Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 23:1215-1222
14. Hamburg MA (2011) Advancing regulatory science. Science 331:987
15. Iskar M, Zeller G, Zhao X-M, van Noort V, Bork P (2011) Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Curr Opin Biotechnol 23:609-616
16. Jones HM, Parrott N, Jorga K, Lave T (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542
17. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499
18. Kaplowitz N (2013) Avoiding idiosyncratic DILI: two is better than one. Hepatology 58:15-17
19. Khetani SR, Kanchagar C, Ukairo O, Krzyzewski S, Moore A, Shi J, Aoyama S, Aleo M, Will Y (2013) The use of micropatterned cocultures to detect compounds that cause drug induced liver injury in humans. Toxicol Sci 132:107-117
20. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W (2011) Translating clinical findings into knowledge in drug safety evaluation - drug induced liver injury prediction system (DILIps). PLoS Comput Biol 7:e1002310
21. Low Y, Uehara T, Minowa Y, Yamada H, Ohno Y, Urushidani T, Sedykh A, Muratov EN, Kuz'min V, Fourches D, Zhu H, Rusyn I, Tropsha A (2011) Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem Res Toxicol 24:1251-1262
22. Muster W, Breidenbach A, Fischer H, Kirchner S, Muller L, Pahler A (2008) Computational toxicology in drug development. Drug Discov Today 13:303-310
23. O'Brien PJ, Chan K, Silber PM (2004) Human and animal hepatocytes in vitro with extrapolation in vivo. Chem Biol Interact 150:97-114 (Pubitemid 39445376)
24. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56-67
25. Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A (2012) Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci 129:332-345
26. Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Bjornsson T, Lave T, Yates JW (2011) PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 100:4127-4157
27. Rusyn I, Sedykh A, Low Y, Guyton KZ, Tropsha A (2012) Predictive modeling of chemical hazard by integrating numerical descriptors of chemical structures and short-term toxicity assay data. Toxicol Sci 127:1-9
28. Schnackenberg LK, Chen M, Sun J, Holland RD, Dragan Y, Tong W, Welsh W, Beger RD (2009) Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol Appl Pharmacol 235:25-32
29. Shi W, Bessarabova M, Dosymbekov D, Dezso Z, Nikolskaya T, Dudoladova M, Serebryiskaya T, Bugrim A, Guryanov A, Brennan RJ, Shah R, Dopazo J, Chen M, Deng Y, Shi T, Jurman G, Furlanello C, Thomas RS, Corton JC, Tong W, Shi L, Nikolsky Y (2010) Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes. Pharmacogen J 10:310-323
30. Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24:1345-1410
31. Thomas CE, Will Y (2012) The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery. Expert Opin Drug Discov 7:109-122
32. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 25:1616-1632
33. Tolosa L, Pinto S, Donato MT, Lahoz A, Castell JV, O'Connor JE, Gomez-Lechon MJ (2012) Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol Sci 127:187-198
34. Will Y, Schroeter T (2012) Deployment of in silico and in vitro safety assays in early-stage drug discovery. Future Med Chem 4:1211-1213
35. Xu JJ, Diaz D, O'Brien PJ (2004) Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 150:115-128 (Pubitemid 39441298)
36. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:97-105
37. Zhu X, Sedykh A, Liu S (2013) Hybrid in silico models for drug-induced liver injury using chemical descriptors and in vitro cell-imaging information. J Appl Toxicol. doi:10.1002/jat.2879